II. Indication

III. Mechanism

  1. Soluble TNF receptor blocker

IV. Efficacy

  1. Rapid onset and very effective
  2. Arrests XRay progression
  3. Good synergistic effect with Methotrexate

V. Adverse Effects

  1. Potential risk of infection
  2. No significant adverse effects

VI. Dosing

  1. Preloaded vial or syringe: 25 mg SQ twice weekly or 50 mg SC weekly

VII. Cost

  1. Per vial: $150
  2. Per month: $1200
  3. Per year: $14,000

VIII. Monitoring

  1. Consider following Complete Blood Count

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Cost: Medications

enbrel (on 7/1/2016 at Medicaid.Gov Survey of pharmacy drug pricing)
ENBREL 25 MG KIT $499.15 each
ENBREL 25 MG/0.5 ML SYRINGE $985.61 per ml
ENBREL 50 MG/ML SURECLICK SYR $1,024.63 per ml
ENBREL 50 MG/ML SYRINGE $1,026.05 per ml

Ontology: Etanercept (C0717758)

Definition (NCI) A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. (NCI04)
Definition (NCI_NCI-GLOSS) A drug that is commonly used to treat arthritis. It is also being studied in the treatment of cancer, and as a treatment for loss of appetite and weight loss in cancer patients. It belongs to the family of drugs called tumor necrosis factor (TNF) antagonists.
Definition (PDQ) A recombinant soluble dimeric fusion protein consisting of the extracellular ligand-binding region of recombinant human tumor necrosis factor (rhTNF) receptor attached to the constant (Fc) region of human immunoglobulin G (FcIgG). The receptor moiety of etanercept binds to circulating TNF (2 molecules of TNF per receptor) and inhibits its attachment to endogenous TNF cell surface receptors, thereby rendering TNF inactive and inhibiting TNF-mediated mechanisms of inflammation. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257809&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=257809&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2381" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Immunologic Factor (T129) , Amino Acid, Peptide, or Protein (T116)
MSH C106167
SnomedCT 118259007, 387045004
English Tumor Necrosis Factor Receptor IgG Chimera, tumor necrosis factor receptor IgG chimera, etanercept (medication), ETANERCEPT, Etanercept, Etanercept (product), Etanercept (substance), TNFR:Fc, etanercept, ETN
Spanish etanercept (producto), etanercept (sustancia), etanercept

Ontology: Enbrel (C0720193)

Definition (CHV) brand name of a drug that is used to treat rheumatism
Definition (CHV) brand name of a drug that is used to treat rheumatism
Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116)
MSH C106167
English Enbrel, etanercept (Enbrel), enbrel [brand name], enbrel, Immunex brand of etanercept, Wyeth brand of etanercept